Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

13 Mar 2024 15:48

RNS Number : 7499G
GSK PLC
13 March 2024

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 9,000 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.7189

9,000

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 4,340 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.7944

4,340

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dylan Jackson

b)

Position/status

PCA of Sally Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 13,616 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6871

13,616

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dylan Jackson

b)

Position/status

PCA of Sally Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 2,476 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.7145

2,476

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, GSK Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of 60,000 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.8004

60,000

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2024-03-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSFIFIDELSELD
Date   Source Headline
15th Jan 201912:00 pmRNSGlaxoSmithKline Extends Tender Offer for TESARO
11th Jan 20194:32 pmRNSDirector/PDMR Shareholding
11th Jan 20194:25 pmRNSDirector/PDMR Shareholding
2nd Jan 20191:45 pmRNSTotal Voting Rights
20th Dec 20185:15 pmRNSDirector/PDMR Shareholding
19th Dec 20187:00 amRNSGSK and Pfizer create new Consumer Healthcare JV
14th Dec 20181:20 pmRNSGSK Commences Tender Offer for TESARO Inc.
12th Dec 20184:35 pmRNSDirector/PDMR Shareholding
4th Dec 201810:07 amRNSDirector/PDMR Shareholding
3rd Dec 20182:00 pmRNSTotal Voting Rights
3rd Dec 201812:02 pmRNSGSK reaches agreement to acquire TESARO
3rd Dec 20188:35 amRNSGSK to divest Horlicks to Unilever
30th Nov 20184:40 pmRNSSecond Price Monitoring Extn
30th Nov 20184:35 pmRNSPrice Monitoring Extension
29th Nov 20183:40 pmRNSDirector/PDMR Shareholding
29th Nov 201811:45 amRNSGSK - Update on Review of Horlicks
27th Nov 20183:25 pmRNSBlock listing Interim Review
22nd Nov 20181:02 pmRNSGSK publishes 2019 Dividend Dates
12th Nov 20182:45 pmRNSDirector/PDMR Shareholding
12th Nov 20189:00 amRNSBlocklisting Application
8th Nov 201812:43 pmRNSDirector Declaration
2nd Nov 20184:15 pmRNSDirector/PDMR Shareholding
1st Nov 20181:40 pmRNSTotal Voting Rights
31st Oct 20182:15 pmRNSViiV positive phIII results with fostemsavir
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
31st Oct 201812:00 pmRNS3rd Quarter Results
30th Oct 20182:30 pmRNSViiV: positive data for long-acting injectable
29th Oct 201810:00 amRNSViiV - three-year data for long-acting injectable
18th Oct 20184:00 pmRNSViiV submits HIV 2DR regulatory application to FDA
18th Oct 20189:34 amRNSDirector/PDMR Shareholding
17th Oct 20185:56 pmRNSDirector/PDMR Shareholding
17th Oct 20185:50 pmRNSDirector/PDMR Shareholding
17th Oct 201811:30 amRNSDirector/PDMR Shareholding
16th Oct 20184:53 pmRNSDirector/PDMR Shareholding
16th Oct 20189:30 amRNSDirector/PDMR Shareholding
16th Oct 20189:30 amRNSDirector/PDMR Shareholding
10th Oct 20183:30 pmRNSDirector/PDMR Shareholding
1st Oct 20181:58 pmRNSTotal Voting Rights
27th Sep 20184:35 pmRNSDirector/PDMR Shareholding
21st Sep 201812:30 pmRNSCHMP recommends expansion of Trelegy COPD label
14th Sep 20189:00 amRNSViiV submits HIV 2DR regulatory application to EMA
12th Sep 20185:43 pmRNSDirector/PDMR Shareholding
10th Sep 20188:00 amRNSNew analysis on efficacy of anti-IL5 biologics SEA
10th Sep 20187:00 amRNSGSK receives CRL from FDA for mepolizumab in COPD
7th Sep 20182:24 pmRNSDirector/PDMR Shareholding
7th Sep 20182:18 pmRNSDirector/PDMR Shareholding
3rd Sep 20185:00 pmRNSTotal Voting Rights
30th Aug 20185:12 pmRNSGSK publishes Q4 2018 Dividend Dates
30th Aug 20188:12 amRNSEU approve Nucala in severe asthma in children

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.